Stripe, Anthropic, OpenAI launch nonprofit to tackle respiratory viruses with nasal sprays and air tech

Stripe, Anthropic, and OpenAI have launched a nonprofit initiative targeting respiratory infections — the colds, flus, and other airborne viruses that collectively cause illness on a scale comparable to waterborne diseases a century ago. The founders of Stripe convened a symposium with 40 researchers last year to assess the technical feasibility of a population-level solution. The consensus: cautiously optimistic, but no single technology will suffice. Even a vaccine or pill offering 90 percent protection against 90 percent of respiratory viruses would fall short of herd immunity at realistic uptake rates around 60 percent, based on current vaccination data.

The nonprofit is pursuing two parallel tracks. On the pharmaceutical side, one approach involves virus-trapping proteins delivered as a nasal spray to intercept pathogens before infection takes hold; other formats remain under consideration. On the air-quality side, the group is evaluating antimicrobial lamps, air filtration systems, and antimicrobial vapors — technologies that have shown promise in reducing airborne pathogen concentrations by more than 75 percent but need further safety testing and cost optimization for deployment in high-transmission indoor settings. The initiative is targeting a 4-7 year timeline to bring candidate technologies through late-stage clinical testing.